Sintilimab: all 353 studies that test it
Page 2 of 4. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.
- A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCNot yet recruitingNCT06485557Phase 3
- A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
- Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB PatientsRecruitingNCT06457477Not applicable
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.RecruitingNCT06421298Phase 2
- Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06413342Phase 2
- Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
- Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical CancerRecruitingNCT06391190Phase 1/2
- Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
- Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
- Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALMRecruitingNCT06341595Phase 2
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell LymphomaRecruitingNCT06314334Phase 2
- Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)RecruitingNCT06313190Phase 2
- Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingNCT06308939Phase 2
- Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06285019Phase 2
- A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral BloodRecruitingNCT06240689Phase 2
- Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung CancerNot yet recruitingNCT06221462Phase 2
- The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent GlioblastomaRecruitingNCT06220552Phase 2
- Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal CancerRecruitingNCT06204094Phase 2
- A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCRecruitingNCT06190639Phase 2
- Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical ResectionNot yet recruitingNCT06161909Phase 3
- A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2
- Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular CarcinomaRecruitingNCT06141109Phase 1/2
- A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionNot yet recruitingNCT06089382Phase 3
- Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular InvasionNot yet recruitingNCT06089369Phase 3
- IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingNCT06078657Phase 2
- bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicable
- Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
- Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical TrialRecruitingNCT06031285Phase 2
- The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.RecruitingNCT06029829Phase 2
- Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric CancerRecruitingNCT05982301Phase 2
- Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05979818Phase 1
- Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
- A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid TumorsRecruitingNCT05940181Not applicable
- The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05839275Phase 1/2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- A Study of RC88 Combined With Sintilimab for Advanced Solid TumoursRecruitingNCT05804526Phase 1/2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
- HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT05648487Phase 2
- First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm TrialRecruitingNCT05648071Phase 3
- Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) PatientsRecruitingNCT05638451Phase 2
- Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
- A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Not yet recruitingNCT05594381Phase 2
- Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingNCT05562297Phase 2
- Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsNot yet recruitingNCT05527821Phase 2
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
- Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05495152Phase 3
- Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal CancerNot yet recruitingNCT05484024Phase 2/3
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
- Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal CancerRecruitingNCT05450029Phase 2
- Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）RecruitingNCT05429463Phase 3
- PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)RecruitingNCT05357846Phase 3
- Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
- First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPNot yet recruitingNCT05280626Phase 2
- TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3
- Sintilimab Plus NCT or NCRT Versus NCRT for ESCCNot yet recruitingNCT05244798Phase 3
- PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal CancerRecruitingNCT05236972Phase 3
- A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
- SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaNot yet recruitingNCT05218148Phase 2
- A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) CancerRecruitingNCT05216237Phase 2
- First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaRecruitingNCT05188859Phase 2
- Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction AdenocarcinomaRecruitingNCT05170503Phase 2
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
- Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)RecruitingNCT05098119Phase 2
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingNCT05057052Phase 2
- Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
- Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05004974Phase 2
- Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsRecruitingNCT05000892Phase 2
- Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCLRecruitingNCT04994210Phase 2
- Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung CancerRecruitingNCT04973293Not applicable
- Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System LymphomaRecruitingNCT04961515Phase 2
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerNot yet recruitingNCT04958473Phase 2
- Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical CancerRecruitingNCT04918628Phase 2
- Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent MeningiomaRecruitingNCT04728568Not applicable
- Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCLNot yet recruitingNCT04659434Phase 2
- Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal CancerRecruitingNCT04636008Phase 1/2
- Adriamycin and Ifosfamide Combined With SintilimabRecruitingNCT04589754Phase 2
- Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaRecruitingNCT04512534Phase 2
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
- Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCLNot yet recruitingNCT04052659Phase 2
- Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
- Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer StudyTerminatedNCT05026736Phase 2Results posted
- Sintilimab in Cancer of Unknown PrimaryCompletedNCT05024968Phase 2Results posted
- Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer StudyTerminatedNCT05017103Phase 2Results posted
- Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC PatientsCompletedNCT03812549Phase 1Results posted
- Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLCCompletedNCT03629925Phase 3Results posted
- Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCCompletedNCT03607539Phase 3Results posted
- IBI308 in Subjects With Advanced/Metastatic Solid MalignanciesCompletedNCT03568539Phase 1Results posted
- Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma PatientsCompletedNCT03228836Phase 2Results posted
- A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLCCompletedNCT03150875Phase 3Results posted
- Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line TreatmentCompletedNCT03116152Phase 2Results posted
- First in Human Study of IBI308 in Chinese Subjects With Advanced Solid TumorsCompletedNCT02937116Phase 1Results posted
- Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical StudyActive, not recruitingNCT07306663Phase 3
- CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric CancerActive, not recruitingNCT06667050Phase 2
- Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Phase 2
- Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsActive, not recruitingNCT06220318Phase 1/2
- Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical TrailCompletedNCT06108596Phase 2
- The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
- Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric CancerActive, not recruitingNCT05795296Phase 2